- Home
- SLNO vs HTFL Comparison
SLNO vs HTFL Comparison
Compare SLNO & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLNO | HTFL |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | 843 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLNO | HTFL |
|---|---|---|
| Price | $53.01 | $31.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $83.00 | $38.20 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.90 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,450,788.00 | N/A |
| Revenue This Year | $150.46 | $27.66 |
| Revenue Next Year | $50.37 | $23.55 |
| P/E Ratio | $89.83 | ★ N/A |
| Revenue Growth | ★ 138.82 | N/A |
| 52 Week Low | $29.43 | $20.13 |
| 52 Week High | $89.12 | $41.22 |
Technical Indicators
Market Signals| Indicator | SLNO | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 77.32 | 57.62 |
| Support Level | $48.91 | $28.60 |
| Resistance Level | $55.47 | $32.71 |
| Average True Range (ATR) | 0.05 | 2.17 |
| MACD | -0.52 | 0.18 |
| Stochastic Oscillator | 100.00 | 85.12 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.